Physician profile
Robert L Carlin
NPI 1609872167
$776.09
in general payments reported to CMS, 2019-2025
11 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.38 · 2020: $79.89 · 2021: $307 · 2022: $72.53 · 2023: $127 · 2024: $47.76 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $173.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $117.64 | 2020-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $106.85 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $100.29 | 2024-2025 | Terlivaz |
| Abiomed | $79.27 | 2023 | Impella |
| Pfizer INC. | $54.89 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.94 | 2020-2022 | |
| Philips North America LLC | $25.69 | 2025 | Vest Therapy Und |
| Cmp Pharma, INC. | $24.99 | 2023 | Norliqva, Tadliq, Carospir |
| Abbvie INC. | $22.86 | 2023 | Teflaro, Dalvance, Avycaz |
| Smith+Nephew, INC. | $15.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.